Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12924MR)

This product GTTS-WQ12924MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12924MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7880MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ1619MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ12960MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ1810MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ11699MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ1556MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ6810MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ8126MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW